Kyung Nam Pharm KRX:053950KOSDAQ
경남제약 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days1
DART filings, 7 days0
Articles tracked1since Sep 11
In Q2 2026, Kyung Nam Pharm reported revenue of ₩17.8bn, up 26.9% year on year, and an operating loss of ₩212m. Kyung Nam Pharm (경남제약) appeared in 1 Korean news article and 0 DART filings over the past seven days. Coverage peaked on Sep 11 with 1 article.
Kyung Nam Pharm quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩17.8bn | +26.9% | −₩212m | −₩3.4bn |
| Q1 2026 | ₩16.1bn | +23.2% | ₩377m | −₩858m |
| Q4 2025 derived | ₩14.7bn | -9.0% | ₩66m | −₩5.3bn |
| Q3 2025 | ₩14.2bn | -1.2% | −₩1.1bn | −₩4.7bn |
| Q2 2025 | ₩14.0bn | -8.4% | −₩839m | ₩2.5bn |
| Q1 2025 | ₩13.1bn | -26.0% | ₩106m | −₩1.6bn |
| Q4 2024 derived | ₩16.1bn | +3.2% | ₩273m | −₩2.0bn |
| Q3 2024 | ₩14.3bn | +2.4% | −₩202m | −₩4.2bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Kyung Nam Pharm top stories 2 weeks, by number of outlets
- 1